RAD51 is a poor prognostic marker and a potential therapeutic target for oral squamous cell carcinoma

Table 1 RAD51 was an independent risk factor for PFS and OS in OSCC patients receiving chemotherapy

(A)	Univariate analysis of PFS		(B)	Univariate analysis of OS		Multivariable analysis of OS
Variables	HR (95%CI)	P-value	Variables	HR (95%CI)	P-value	HR (95%CI)	P-value
Sex			Gender
Male	1.00		Male	1.00
Female	0.04 (0.00-13.52)	0.282	Female	0.05 (0.0-852.71)	0.538
Age	1.01 (0.98–1.05)	0.478	Age	1.02 (0.97–1.08)	0.398
Alcohol consumption	0.93 (0.42–2.07)	0.859	Alcohol consumption	1.66 (0.46–5.99)	0.437
Betel nut chewing	1.53 (0.55–4.07)	0.395	Betel nut chewing	1.53 (0.34–6.87)	0.581
Cigarette smoking	0.83 (0.37–1.90)	0.663	Cigarette smoking	1.35 (0.37–4.84)	0.650
Stage		0.702	Stage		0.029*		0.029*
I, II	1.00		I, II	1.00		1.00
III, IV	0.87 (0.41–1.82)		III, IV	3.34 (1.13–9.82)		3.39 (1.13–10.13)
RAD51 expression		0.035*	RAD51 expression		0.013*		0.013*
Low expression	1.00		Low expression	1.00		1.00
High expression	2.36 (1.06–5.23)		High expression	5.18 (1.42–18.87)		5.27 (1.43–19.47)

(A). Univariate Cox regression analysis of Progression free survival (PFS) in OSCC patients receiving adjuvant chemotherapy and RAD51 was the only independent risk factor for PFS. (B). Univariate and multivariate Cox regression analyses of overall survival (OS) in OSCC patients receiving adjuvant chemotherapy. Stage and RAD51 expression were the two poor prognostic factors for OS
*PFS, progression-free survival; OS, overall survival; OSCC, oral squamous cell carcinoma; HR, hazard ratio; CI, confidence interval

ISSN: 1475-2867